A   B   C   D   E   F   G   H   I   J   K   L   M   N   O   P   Q   R   S   T   U   V   W   X   Y   Z  

Chubarov, O.

Paper Title Page
MOPD095 Various Improvements to Operate the 1.5 GeV HDSM at MAMI 927
 
  • M. Dehn, O. Chubarov, H. Euteneuer, R.G. Heine, A. Jankowiak, H.-J. Kreidel, O. Ott
    IKP, Mainz
 
 

Dur­ing the last three years at the 1.5 GeV Har­mon­ic Dou­ble Sided Mi­crotron (HDSM)* of MAMI a lot of im­prove­ments con­cern­ing the lon­gi­tu­di­nal op­er­a­tion of the ac­cel­er­a­tor were test­ed and in­stalled. To mon­i­tor the rf power dis­si­pat­ed in the ac­cel­er­at­ing sec­tions, their cool­ing water flow and its tem­per­a­ture rise are now con­tin­u­ous­ly logged. Phase cal­i­bra­tion mea­sure­ments of the linacs and the rf-mon­i­tors re­vealed non­lin­ear­i­ties of the high pre­ci­sion step-mo­tor driv­en waveg­uide phase shifters. They were re­cal­i­brat­ed to de­liv­er pre­cise ab­so­lute val­ues. There­by it is now pos­si­ble to mea­sure not only the first turn's phase very ex­act­ly, but also de­ter­mine the linac's rf-am­pli­tude with­in an error of less than 5%, using the well known lon­gi­tu­di­nal dis­per­sion of the bend­ing sys­tem. These re­sults are com­pared to the ther­mal load mea­sure­ments. For par­i­ty vi­o­lat­ing ex­per­i­ments the beam en­er­gy has to be sta­bilised to some ppm. A ded­i­cat­ed sys­tem mea­sur­ing the time-of-flight through a bend­ing mag­net is now used in rou­tine op­er­a­tion and con­trols the out­put en­er­gy via the prop­er linac phas­es.


* K.-H. Kaiser et al., NIM A 593 (2008) 159 - 170, doi:10.1016/j.nima.2008.05.018

 
THPD025 Recent Status of the MAMI-C Accelerator and First Experiences with the Energy Upgrade towards 1.6 GeV 4328
 
  • R.G. Heine, K. Aulenbacher, M. Dehn, H. Euteneuer, A. Jankowiak, P. Jennewein, H.-J. Kreidel, U. Ludwig-Mertin, O. Ott, G.S. Stephan, V. Tioukine
    IKP, Mainz
  • O. Chubarov
    Siemens AG, Erlangen
 
 

The uni­ver­si­ty of Mainz in­sti­tute for nu­cle­ar physics is op­er­at­ing the mi­crotron cas­cade MAMI (Mainz­er Mikrotron) since the late 1970ies. The mi­crotron de­liv­ers a cw elec­tron beam to users of the hadron physics com­mu­ni­ty. The re­cent, fourth stage MA­MI-C hav­ing a de­sign en­er­gy of 1.5 GeV is op­er­at­ed since 2006*. This ar­ti­cle deals with the re­cent de­vel­op­ments and op­er­a­tional ex­pe­ri­ences of MA­MI-C, as well as with the en­er­gy up­gardes to 1.56 GeV** and as final step to­wards 1.6 GeV. The final in­crease of beam en­er­gy was due to user de­mands, since it is ex­pect­ed to raise the event rate of the eta prime pro­duc­tion by an order of mag­ni­tude.


* A.Jankowiak, et al., EPAC08, Genoa, Italy, p.51 (MOZCM01)
** A. Jankowiak, et al., PAC09, Vancouver, Canada (WE6PFP111)

 
MOPEA005 Status of the SIEMENS Particle Therapy Accelerators 70
 
  • P. Urschütz, O. Chubarov, S. Emhofer, S. Göller, K. Haß, C.M. Kleffner, V.L. Lazarev, M. Leghissa, M.T. Maier, D. Ondreka, H. Rohdjess, R. Rottenbach, A.C. Sauer, R. Schedler, B. Schlitt, P. Schütt, B. Steiner, J. Tacke, T. Uhl, U. Weinrich, O. Wilhelmi
    Siemens Med, Erlangen
  • H.K. Andersen, M. Budde, F. Bødker, J.S. Gretlund, H.B. Jeppesen, C.V. Nielsen, C.G. Pedersen, Ka.T. Therkildsen, S.V. Weber
    Siemens DK, Jyllinge
  • E. Tanke
    FRIB, East Lansing, Michigan
 
 

Siemens has earned three con­tracts to de­liv­er ION­TRIS Par­ti­cle Ther­a­py ac­cel­er­a­tor sys­tems* to be op­er­at­ed in Mar­burg and Kiel, both in Ger­many, and in Shang­hai, China. The ac­cel­er­a­tor part con­sists of an in­jec­tor (7 MeV/u pro­tons and light ions) and a com­pact syn­chrotron able to ac­cel­er­ate pro­ton beams up to 250 MeV and car­bon ions up to 430 MeV/u. These beams can be slow­ly ex­tract­ed and de­liv­ered to a choice of fixed-an­gle hor­i­zon­tal, se­mi-ver­ti­cal and ver­ti­cal beam-ports. An overview of the de­sign will be given and the sta­tus of the in­stal­la­tion and com­mis­sion­ing work for the first two pro­jects will be shown.


*Particle Therapy is a work in progress and requires country-specific regulatory approval prior to clinical use.